Shanghai Henlius Biotech has celebrated an Australian approval for its Hanquyou trastuzumab biosimilar rival to Herceptin, which has been approved by the country’s TGA under the names Tuzucip and Trastucip via local partner Cipla.

Following ABL Bio’s sizable Parkinson’s disease drug deal with Sanofi early this year, Korean bioventure Kainos Medicine is under the spotlight as its novel PD drug candidate enters Phase II in the US.

The first half of 2022 saw a total of seven promising treatments for unmet medical needs make it onto the European Medicines Agency’s priority medicine scheme.

A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.